IP Group PLC (IPO) — Research Note

Executive summary

IP Group is a UK-listed closed-end investment vehicle that creates, backs and grows early-stage science and technology companies spun out of leading universities (Oxford, Cambridge, Imperial, UCL plus Australian partners), with 86 portfolio companies spread across HealthTech (60%), CleanTech (19%), DeepTech (14%) and platform fund interests. Over the past five years the Group has swung violently with its portfolio marks — a £449m profit in 2021 on the Oxford Nanopore IPO was followed by three loss years (2022-2024 cumulative loss £725m) before 2025-26 recovery driven by crystallising a c.£150m royalty asset on Pfizer's obesity drug portfolio (via former portfolio company Zihipp/Metsera). The single most important valuation anchor today is the gap between the 30 June 2026 NAV of 113.9p (post-period 117p) and the 68.4p share price — a c.42% discount — set against the fact that NAV itself is dominated by illiquid Level 3 fair values whose integrity has been repeatedly tested by writedowns.

Fair value estimate

Methodology: discount-to-NAV, which is the standard approach for a listed venture investment company. Portfolio companies are already marked to fair value using DCF (Pfizer royalty, Istesso), quoted prices (Oxford Nanopore, Centessa), funding-round calibration and PWERM, so a sum-of-parts rebuild is largely redundant — the right question is what discount a buyer should demand.

Inputs:

• Reported NAV at 11 September 2026: ~117p per share, £1,033m total 2026-09 half-year
• UK listed venture-trust peers (Molten Ventures, Oakley Capital, Augmentum Fintech) typically trade at 25-40% discounts to NAV; the current 42% discount is at the wide end
• Argument for narrower discount: Pfizer royalty is a contracted cash stream (not a venture outcome); the Group holds £239m gross cash; recent realisations (Hinge £46m total/53x, Centessa £18m, Monolith/CoreWeave £23m) validate the carrying marks
• Argument for wider discount: Istesso's 2024 Phase 2b missed its primary endpoint, resulting in a £33m writedown 2026-03 FY25 results; the June 2026 buyback resolution failed to pass 2026-06 AGM; valuation of the Pfizer royalty (£152m, 15% of NAV) is DCF-based with ±5% clinical-success rate sensitivity of +£29m / -£24m

Fair-value range: apply a 25-35% discount to 117p NAV → 76p – 88p per share, implying a market cap of £671m – £778m.

• Mid-point: 82p / £724m
• vs latest £604m market cap → absolute upside c.+20%

Sector context

Confirmed as Financial Services / Equity Investment Instruments. Compared with peers:

• vs 3i Group: much weaker — 3i runs a leveraged private-equity model with Action compounder; IPO is pre-revenue VC
• vs Molten Ventures: similar risk profile (tech VC), similar discount dynamic; Molten more digital/software weighted
• vs Oakley Capital Investments / HgCapital Trust: those are mature PE buyout vehicles with proven cash yields; IPO is riskier, earlier-stage
• Listed peers for valuation triangulation: Molten Ventures (GROW), Oakley Capital Investments (OCI), Augmentum Fintech (AUGM)

Quality/growth/leverage profile is below average vs this peer set — IPO portfolio is earlier-stage, more biotech-weighted, and NAV has compounded poorly over 5 years (167p FY21 → 113.9p HY26, a 32% decline despite net share count reduction from buybacks).

Investment thesis (3 bullets)

1. Pfizer obesity royalty is a genuine asymmetric option — IP Group retains contractual exposure to berobenatide and the amylin combination (now Phase 2b with 39% probability of success), licence + deferred Zihipp consideration valued at £152m, split 50/50 with Imperial College. Pfizer is running a ten-trial Phase 3 programme targeting 2028 launch into an estimated $150bn obesity market. 2026-09 half-year
2. Discount provides margin of safety on a net-cash investment vehicle — £239m gross cash, £120m fixed-rate 5.25% debt (so net cash ~£119m is 20% of market cap), portfolio value £907m, and £85m of 2026 realisations already in the bag. On breakup, the quoted portfolio alone (ONT + Centessa fragment: £102m) plus net cash covers roughly 37% of current market cap. 2026-09 half-year
3. Monetisation path is being executed — £137m realised against the £250m 2025-27 exit target with a maturing portfolio including Oxford Quantum Circuits (£260m Series C), Quantum Motion ($160m Series C), Hinge Health full exit at 53x MoIC, Centessa acquisition by Lilly. Portfolio companies raised £543m in H1 2026 with IPO contributing only 5%, demonstrating third-party validation of marks. 2026-09 half-year

Key risks (3 bullets)

1. Pfizer drug trial failure risk — the DCF model assumes zero recovery if a compound fails Phase 3; applied success rates are 53% for berobenatide and 39% for the combination 2026-09 half-year, note 5A. A single failure could remove £50-80m of NAV. GLP-1 competition from Lilly/Novo may also compress commercial assumptions even if the drug reaches market.
2. Early-stage venture concentration and valuation opacity — 91% of portfolio value sits in 40 holdings; 43% of 2026 H1 funding rounds were "down rounds" (vs 38% H1 25) 2026-09 half-year. Three Level-3-marked DeepTech holdings (Diffblue, Aqdot, Ultraleap) wrote down a combined £11.7m in H1 2026 alone. Pattern of writedowns in 2022-24 (Oxa -£30.5m, Pulmocide -£24.1m, First Light Fusion -£40m, Istesso -£33m) suggests NAV will keep oscillating.
3. Governance friction limits NAV-discount closure — the June 2026 AGM saw resolutions 13, 14 and 16 (buyback authority, pre-emption disapplication) fail to pass; £50m of accumulated proceeds earmarked for buybacks are now stuck pending shareholder engagement 2026-06 AGM; 2026-09 half-year. The 2025-27 buyback mechanism was the primary tool for narrowing the discount; without it the 42% discount may persist.

Operating leverage

IP Group is not an operating business in the sense this investor framework contemplates. Its "revenue" is portfolio fair-value movements, not customer sales; its cost base is £16-20m of annual group overheads (net overheads £7.9m HY26, £15.9m FY25) against a £907m portfolio — so cost/NAV is only ~1.6%. There is no "incremental revenue drops to profit" dynamic. The leverage that does exist is portfolio-outcome leverage: a single successful exit (Hinge Health delivered 53x MoIC, £46m cash on <£1m invested) can move NAV materially, but the correlation to "AI cycle delivers more revenue than planned" is weak because the biggest driver is a Pfizer-controlled drug approval event. Operating leverage score should therefore be low — this stock does not fit the "high-fixed-cost business whose profits explode on incremental demand" criterion the strategy is seeking.

Value-trap signals

• Persistent 40%+ discount to NAV through multiple cycles including the 2025-26 recovery
• NAV per share compounded negatively 2021 → HY26 (167p → 113.9p, -32%) despite 17.7% share-count reduction via buybacks since 2021
• Dividends suspended since 2024; dividend/buyback resolutions failed at June 2026 AGM
• Repeated large writedowns on flagship private holdings (Pulmocide, Oxa, Istesso, First Light Fusion, Diffblue, Aqdot) — the "lumpy mark-to-model" pattern is a hallmark of value traps in listed VC trusts
• Related-party structure: 50% of Pfizer royalty cash flow is payable to Imperial College London under the historic TPA (reducing headline optionality by half)

Earnings vs expectations

IP Group doesn't guide to EPS and reports on a NAV-return basis against internal targets (which drive incentive compensation but aren't externally benchmarked by consensus in the usual way). Looking at NAV return per share versus the implicit 15% CAGR LTIP vesting thresholds of prior schemes: 2021 beat substantially (ONT IPO), 2022-24 missed heavily (three consecutive loss years), 2025-26 modestly beat as the Pfizer royalty crystallised. The "£250m exits 2025-27" target is on track (£154m delivered through 11 September 2026). The pattern is highly binary — this is not a steady-beat stock, more a mix of occasional large positive surprises offset by multi-year drawdowns.

Conviction

Conviction: 3 (moderate).

• Supporting: NAV mechanics are well-disclosed with Level 1/3 breakdowns and sensitivity tables; the discount approach is the industry-standard methodology; net cash position provides a hard floor.
• Limiting: ~£800m of NAV sits in Level 3 fair values dependent on DCFs and funding-round calibration — a reasonable alternative mark could be 10-20% lower; the Pfizer royalty valuation alone could swing ±£50m on clinical outcomes; peer discount benchmarking is imprecise.

Driver scoring and overall rationale

This stock is a weak fit for the strategy: AI-receiver exposure is thin (quantum computing holdings are small and early; the "AI-driven pharma platform" angle is indirect at best), there is no meaningful operating leverage because this is a holding vehicle, and while the discount provides downside support, the thing being discounted is itself a volatile mark-to-model NAV. Overall score 335.